SCHEMBL19420533

SCHEMBL19420533

C=C(C)NS(=O)(=O)c1ccc(NC2=CC(=O)c3ccccc3C2=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 9/20 0.61
▸ KMT2A Q03164 9/20 0.61
▸ RAB9A P51151 7/20 0.61
▸ NPC1 O15118 7/20 0.61
▸ MAPT P10636 7/20 0.59
▸ BLM P54132 7/20 0.59
▸ MAPK1 P28482 4/20 0.59
▸ TDP1 Q9NUW8 4/20 0.59
▸ JAK2 O60674 1/20 0.59
▸ EPHB2 P29323 1/20 0.59
▸ SMN1; SMN2 Q16637 6/20 0.57
▸ L3MBTL1 Q9Y468 5/20 0.57
▸ HTT P42858 5/20 0.57
▸ LMNA P02545 4/20 0.57
▸ ALDH1A1 P00352 4/20 0.57
▸ NFKB1 P19838 1/20 0.57
▸ NFKB2 Q00653 1/20 0.57
▸ RELA Q04206 1/20 0.57
▸ APAF1 O14727 9/20 0.49
▸ CASP3 P42574 5/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17594379 0.89 RAB9A (0.70) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL2244803 0.81 RAB9A (0.59) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL29597370 0.77 L3MBTL1 (0.78) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL16296690 0.77 L3MBTL1 (0.78) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL29633237 0.75 RAB9A (1.00) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL14571425 0.75 MAPT (0.77) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL28736227 0.75 RAB9A (1.00) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL29633218 0.75 MAPT (0.77) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL7912631 0.75 MAPT (0.80) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL754259 0.74 MAPT (1.00) MEN1KMT2ARAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170283374-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA PELLFICURE PHARMACEUTICALS, INC. 2017-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170283374-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA KLK3, ACP3, NR5A1 MEN1 260/4885KMT2A 3314/4885RAB9A 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback